Review
. 2021 Jul 15;127(14):2515-2524. doi: 10.1002/cncr.33473. Epub 2021 Apr 7. Characterizing participants in the North Carolina Breast and Cervical Cancer Control Program: A retrospective review of 90,000 women Yi Ren 1 , Cushanta C Horton 2 , Sachiko M Oshima 1 , Samantha M Thomas 1 , Sherry Wright 2 , Awanya Caesar 3 , Jennifer K Plichta 1 , E Shelley Hwang 1 , Rachel A Greenup 1 , Laura H Rosenberger 1 , Gayle D DiLalla 1 , Carolyn S Menendez 1 , Lisa Tolnitch 1 , Terry Hyslop 1 , Debi Nelson 2 , Oluwadamilola M Fayanju 1Affiliations
AffiliationsItem in Clipboard
Review
Characterizing participants in the North Carolina Breast and Cervical Cancer Control Program: A retrospective review of 90,000 womenSarah D Tait et al. Cancer. 2021.
. 2021 Jul 15;127(14):2515-2524. doi: 10.1002/cncr.33473. Epub 2021 Apr 7. Authors Sarah D Tait 1 , Yi Ren 1 , Cushanta C Horton 2 , Sachiko M Oshima 1 , Samantha M Thomas 1 , Sherry Wright 2 , Awanya Caesar 3 , Jennifer K Plichta 1 , E Shelley Hwang 1 , Rachel A Greenup 1 , Laura H Rosenberger 1 , Gayle D DiLalla 1 , Carolyn S Menendez 1 , Lisa Tolnitch 1 , Terry Hyslop 1 , Debi Nelson 2 , Oluwadamilola M Fayanju 1 AffiliationsItem in Clipboard
AbstractBackground: The North Carolina Breast and Cervical Cancer Control Program (NC BCCCP) provides breast cancer screening services to underserved women to mitigate disparities in access to care. The authors sought to characterize this understudied population.
Methods: Women 21 years old or older who underwent their first breast cancer screen through NC BCCCP from 2008 to 2018 were included. Demographic factors associated with the timeline of care and odds of a breast cancer diagnosis were identified with negative binomial and logistic regression, respectively.
Results: Of the 88,893 women identified, 45.5% were non-Hispanic (NH) White, 30.9% were NH Black, 19.6% were Hispanic, 1.7% were American Indian, and 1.1% were Asian. Breast cancer was diagnosed in 2.5% of the women (n = 2255). Hispanic women were the least likely to be diagnosed with breast cancer (odds ratio vs NH White women, 0.40; 95% confidence interval [CI], 0.34-0.47). Among patients with breast pathology, the median time to diagnosis was 19 days (interquartile range [IQR], 10-33 days), and the time to treatment was 33 days (IQR, 19-54 days). After adjustments, a longer time to diagnosis was significantly associated with age (incidence rate ratio [IRR], 1.01; 95% CI, 1.01-1.02) and being NH Black (vs NH White; IRR, 1.17; 95% CI, 1.06-1.29). A longer time to treatment was significantly associated with age (IRR, 1.01; 95% CI, 1.01-1.01), being NH Black (vs NH White; IRR, 1.20; 95% CI, 1.10-1.31), and being Hispanic (vs NH White; IRR, 1.22; 95% CI, 1.05-1.41).
Conclusions: NC BCCCP participants with breast cancer received treatment within approximately 1 month of presentation, and this finding aligns with quality care benchmarks. Nevertheless, racial/ethnic disparities in timeliness of care persist, and this suggests opportunities for improvement.
Lay summary: This review of approximately 90,000 participants in a breast cancer screening program for uninsured and underinsured women highlights the importance of safety net programs in providing timely care to underserved patients. The authors found that the North Carolina Breast and Cervical Cancer Control Program met timeliness benchmarks from the Centers for Disease Control and Prevention across all racial/ethnic groups. However, non-Hispanic Black women experienced relative delays in the time to diagnosis, and both non-Hispanic Black women and Hispanic women experienced relative delays in the time to treatment. These findings demonstrate how racial/ethnic disparities in the timeliness of care can persist even within a program intended to reduce barriers to access.
Keywords: breast neoplasms; cancer screening; health care disparities; insurance.
© 2021 American Cancer Society.
Conflict of interest statementCONFLICT OF INTEREST DISCLOSURES
Cushanta C. Horton, Sherry Wright, and Debi Nelson are employed by the North Carolina Department of Health and Human Services. The findings and conclusions presented are those of the researchers and do not represent the views of the North Carolina Department of Health and Human Services, Division of Public Health. Terry Hyslop and Samantha M. Thomas report personal fees from AbbVie outside the submitted work. The other authors made no disclosures.
FiguresFigure 1.
Program participation over time by…
Figure 1.
Program participation over time by race/ethnicity, North Carolina Breast and Cervical Cancer Control…
Figure 1.Program participation over time by race/ethnicity, North Carolina Breast and Cervical Cancer Control Program, 2008–2018. PI indicates Pacific Islander.
Figure 2.
Median timeline of care from…
Figure 2.
Median timeline of care from enrollment, North Carolina Breast and Cervical Cancer Control…
Figure 2.Median timeline of care from enrollment, North Carolina Breast and Cervical Cancer Control Program, 2008–2018.
Similar articlesKong X, Liu Z, Cheng R, Sun L, Huang S, Fang Y, Wang J. Kong X, et al. JAMA Netw Open. 2020 Oct 1;3(10):e2020303. doi: 10.1001/jamanetworkopen.2020.20303. JAMA Netw Open. 2020. PMID: 33074325 Free PMC article.
Dhanjani SA, Gomez G, Rogers D, LaPorte D. Dhanjani SA, et al. Hand (N Y). 2024 May;19(3):471-480. doi: 10.1177/15589447221124248. Epub 2022 Oct 5. Hand (N Y). 2024. PMID: 36196925 Free PMC article.
Holt HK, Peterson CE, MacLaughlan David S, Abdelaziz A, Sawaya GF, Guadamuz JS, Calip GS. Holt HK, et al. JAMA Netw Open. 2023 Mar 1;6(3):e232985. doi: 10.1001/jamanetworkopen.2023.2985. JAMA Netw Open. 2023. PMID: 36897588 Free PMC article.
Olufosoye O, Soler R, Babagbemi K. Olufosoye O, et al. Clin Imaging. 2024 Mar;107:110066. doi: 10.1016/j.clinimag.2023.110066. Epub 2023 Dec 14. Clin Imaging. 2024. PMID: 38228024 Review.
Chen JC, Stover DG, Ballinger TJ, Bazan JG, Schneider BP, Andersen BL, Carson WE, Obeng-Gyasi S. Chen JC, et al. Curr Oncol Rep. 2024 Jan;26(1):10-20. doi: 10.1007/s11912-023-01472-8. Epub 2023 Dec 15. Curr Oncol Rep. 2024. PMID: 38100011 Review.
Manik R, Grady CB, Ginzberg SP, Edmonds CE, Conant EF, Hubbard RA, Fayanju OM. Manik R, et al. JCO Oncol Pract. 2024 Oct;20(10):1367-1375. doi: 10.1200/OP.23.00782. Epub 2024 Jun 20. JCO Oncol Pract. 2024. PMID: 38900977
Cronin KA, Scott S, Firth AU, Sung H, Henley SJ, Sherman RL, Siegel RL, Anderson RN, Kohler BA, Benard VB, Negoita S, Wiggins C, Cance WG, Jemal A. Cronin KA, et al. Cancer. 2022 Dec 15;128(24):4251-4284. doi: 10.1002/cncr.34479. Epub 2022 Oct 27. Cancer. 2022. PMID: 36301149 Free PMC article.
Stevanato KP, Santos LD, Pelloso FC, Borghesan DHP, Consolaro MEL, de Almeida R, Huber IMT, Egger P, Alarcão ACJ, de Souza RR, Ribeiro HF, Camparoto CW, Bitencourt MR, Borba PB, Silva LL, de Barros Carvalho MD, Pelloso SM. Stevanato KP, et al. BMC Womens Health. 2024 Sep 3;24(1):485. doi: 10.1186/s12905-024-03325-3. BMC Womens Health. 2024. PMID: 39227848 Free PMC article.
Brown CM, Kanu C, Richards KM, Stevens L, Sasane R, McAneny B. Brown CM, et al. Cancer Med. 2022 Jun;11(12):2455-2466. doi: 10.1002/cam4.4624. Epub 2022 Mar 10. Cancer Med. 2022. PMID: 35266321 Free PMC article.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3